The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma

被引：0
|
作者：
Rose, April A. N. [1 ]
Armstrong, Susan M. [1 ]
Hogg, David [2 ]
Butler, Marcus [2 ]
Joshua, Anthony M. [3 ]
Ghazarian, Danny [4 ]
Kamel-Reid, Suzanne [4 ]
Al Habeeb, Ayman [4 ]
Chappell, Mary Anne [2 ]
Ross, Kendra [2 ]
Amir, Eitan [2 ]
Bedard, Phillippe L. [2 ]
Siu, Lillian [2 ]
Spreafico, Anna [2 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Kinghorn Canc Ctr, Sydney, NSW, Australia
[4] Univ Hlth Network, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-3141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3141
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma
    Loo, Kimberly
    Daud, Adil
    IMMUNOTHERAPY, 2016, 8 (07) : 775 - 784
  • [32] Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop
    Lorigan, P.
    Eggermont, A. M. M.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1038 - 1040
  • [33] PRIME: An integrative systems immunology approach to predict anti-PD1 responses and discover new targets for melanoma immunotherapy
    Koskela, Saara A.
    Pulkkinen, Otto
    Mehmood, Arfa
    Birkman, Eva-Maria
    Aittokallio, Tero
    Sundvall, Maria
    Figueiredo, Carlos R.
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [34] Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
    Shklovskaya, Elena
    Pedersen, Bernadette
    Stewart, Ashleigh
    Simpson, Jack O. G.
    Ming, Zizhen
    Irvine, Mal
    Scolyer, Richard A.
    Long, Georgina, V
    Rizos, Helen
    CANCERS, 2022, 14 (19)
  • [35] 18F-fluorodeoxyglucose PET/CT imaging for predicting treatment response in patients with advanced melanoma treated with anti-PD1 immunotherapy
    Pampaloni, Miguel Hernandez
    Ashworth, Michelle T.
    Algazi, Alain Patrick
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Development of the combination therapy of anti-PD1 antibody with PAI-1 inhibitors in advanced melanoma patients
    Fujimura, T.
    Ohuchi, K.
    Kambayashi, Y.
    Hidaka, T.
    Asano, Y.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S257 - S257
  • [37] A PHASE II TRIAL OF NIVOLUMAB PLUS AXITINIB IN PATIENTS WITH ANTI-PD1 REFRACTORY ADVANCED MELANOMA
    Shaikh, Saba
    Zang, Yan
    Wang, Hong
    Yang, Xi
    Sander, Cindy
    Rose, Amy
    Davar, Diwakar
    Luke, Jason
    Zarour, Hassane
    Kirkwood, John
    Delgoffe, Greg
    Najjar, Yana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A265 - A265
  • [38] A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma
    Joshi, Urvashi Mitbander
    Shaikh, Saba
    Zang, Yan
    Wang, Hong
    Sander, Cindy
    Rose, Amy
    Davar, Diwakar
    Luke, Jason J.
    Zarour, Hassane M.
    Kirkwood, John M.
    Delgoffe, Greg M.
    Najjar, Yana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] COMBINATION OF FECAL MICROBIOTA TRANSPLANTATION FROM HEALTHY DONORS WITH ANTI-PD1 IMMUNOTHERAPY IN TREATMENT-NAIVE ADVANCED OR METASTATIC MELANOMA PATIENTS
    Maleki, Saman
    Lenehan, John
    Burton, Jeremy
    Silverman, Michael
    Parvathy, Seema Nair
    El-Hajjar, Mikal
    Krishnamoorthy, Mithunah
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A11 - A12
  • [40] Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
    Rogala, Pawel
    Czarnecka, Anna M.
    Cybulska-Stopa, Bozena
    Ostaszewski, Krzysztof
    Piejko, Karolina
    Zietek, Marcin
    Dziura, Robert
    Rutkowska, Ewa
    Galus, Lukasz
    Kempa-Kaminska, Natasza
    Seredynska, Joanna
    Bal, Wieslaw
    Kozak, Katarzyna
    Surus-Hyla, Anna
    Kubiatowski, Tomasz
    Kaminska-Winciorek, Grazyna
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    CANCERS, 2022, 14 (09)
12345